Janet R Vos1, Geertruida H de Bock2, Natalia Teixeira3, Dorina M van der Kolk4, Liesbeth Jansen5, Marian J E Mourits3, Jan C Oosterwijk4. 1. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: j.r.vos01@umcg.nl. 2. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Gynecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Risk estimates for proven non-carriers in BRCA mutation families are inconsistent for breast cancer and lacking for ovarian cancer. We aimed to assess the age-related risks for breast and ovarian cancer for proven non-carriers in these families. METHODS: A consecutive cohort study ascertained 464 proven non-carriers who had a first-degree relative with a pathogenic BRCA mutation. Kaplan-Meier analyses were used to estimate the age-related cancer risks, and we calculated standardised incidence ratios. RESULTS: In the 464 non-carriers, 17 breast cancers and two ovarian cancers were detected at a mean age of 47 years (95% confidence interval (CI) 32-61) and 49 years (95% CI 32-67), respectively. Overall, by the age of 50, the breast and ovarian cancer risks among non-carriers were 6.4% (95% CI 2.9-9.8%) and 0.4% (95% CI 0-1.3%), of which the breast cancer risk was statistically significantly higher than the risk in the general population. In particular, the number of breast cancers among non-carriers in BRCA1 families was higher than expected for the general population (standardised incidence ratio (SIR) 2.0, 95% CI 1.1-3.3). In the BRCA1 cohort, the mean number of breast cancer cases was higher in families in which non-carriers were diagnosed before the age of 50 (p=0.04). CONCLUSION: The age at diagnosis of breast cancer in non-carriers in BRCA mutation families is younger than expected, yielding an increased risk in the fifth decade. This effect is most evident in BRCA1 families. If our results are confirmed by others, this could affect the advice given on breast cancer screening to proven non-carriers between the age of 40 and 50 in such families.
BACKGROUND: Risk estimates for proven non-carriers in BRCA mutation families are inconsistent for breast cancer and lacking for ovarian cancer. We aimed to assess the age-related risks for breast and ovarian cancer for proven non-carriers in these families. METHODS: A consecutive cohort study ascertained 464 proven non-carriers who had a first-degree relative with a pathogenic BRCA mutation. Kaplan-Meier analyses were used to estimate the age-related cancer risks, and we calculated standardised incidence ratios. RESULTS: In the 464 non-carriers, 17 breast cancers and two ovarian cancers were detected at a mean age of 47 years (95% confidence interval (CI) 32-61) and 49 years (95% CI 32-67), respectively. Overall, by the age of 50, the breast and ovarian cancer risks among non-carriers were 6.4% (95% CI 2.9-9.8%) and 0.4% (95% CI 0-1.3%), of which the breast cancer risk was statistically significantly higher than the risk in the general population. In particular, the number of breast cancers among non-carriers in BRCA1 families was higher than expected for the general population (standardised incidence ratio (SIR) 2.0, 95% CI 1.1-3.3). In the BRCA1 cohort, the mean number of breast cancer cases was higher in families in which non-carriers were diagnosed before the age of 50 (p=0.04). CONCLUSION: The age at diagnosis of breast cancer in non-carriers in BRCA mutation families is younger than expected, yielding an increased risk in the fifth decade. This effect is most evident in BRCA1 families. If our results are confirmed by others, this could affect the advice given on breast cancer screening to proven non-carriers between the age of 40 and 50 in such families.
Authors: Annelot Baert; Julie Depuydt; Tom Van Maerken; Bruce Poppe; Fransiska Malfait; Tim Van Damme; Sylvia De Nobele; Gianpaolo Perletti; Kim De Leeneer; Kathleen B M Claes; Anne Vral Journal: Oncol Rep Date: 2017-01-25 Impact factor: 3.906
Authors: Fabio Girardi; Daniel R Barnes; Daniel Barrowdale; Debra Frost; Angela F Brady; Claire Miller; Alex Henderson; Alan Donaldson; Alex Murray; Carole Brewer; Caroline Pottinger; D Gareth Evans; Diana Eccles; Fiona Lalloo; Helen Gregory; Jackie Cook; Jacqueline Eason; Julian Adlard; Julian Barwell; Kai Ren Ong; Lisa Walker; Louise Izatt; Lucy E Side; M John Kennedy; Marc Tischkowitz; Mark T Rogers; Mary E Porteous; Patrick J Morrison; Ros Eeles; Rosemarie Davidson; Katie Snape; Douglas F Easton; Antonis C Antoniou Journal: Genet Med Date: 2018-03-22 Impact factor: 8.822
Authors: S Guedaoura; S Pelletier; W D Foulkes; P Hamet; J Simard; N Wong; Z El Haffaf; J Chiquette; M Dorval Journal: Curr Oncol Date: 2017-12-20 Impact factor: 3.677
Authors: Hildur Helgadottir; Håkan Olsson; Margaret A Tucker; Xiaohong R Yang; Veronica Höiom; Alisa M Goldstein Journal: Genet Med Date: 2017-12-07 Impact factor: 8.822
Authors: David Chelmow; Mark D Pearlman; Amy Young; Laura Bozzuto; Sandra Dayaratna; Myrlene Jeudy; Mallory E Kremer; Dana Marie Scott; Julia Sage O'Hara Journal: Obstet Gynecol Date: 2020-06 Impact factor: 7.623